Healthcare

SINGAPORE (Dec 21): Singapore is embracing technology and focusing more on personal health, as an expected doubling of seniors over the next two decades forces the nation to confront politically sensitive decisions on financing and immigration.

SINGAPORE (Dec 12): Medical technology start-up Advent Access has raised $2.6 million in a pre-Series A financing round led by Accuron MedTech, Southeast Asia’s largest medical device company.

SINGAPORE (Dec 7): As allocations to passive strategies register a decline for the third consecutive year, institutional investors are preparing for volatility, asset bubbles and fragile markets ahead in 2018.

NEW YORK (Dec 4): CVS Health Corp. will buy Aetna Inc. for about US$67.5 billion ($91 billion), creating a health-care giant that will have a hand in everything from insurance to the corner drugstore.

SINGAPORE (Nov 9): DBS Vickers Securities has upgraded its view on Singapore O&G (SOG) to “neutral” from “fully valued” while raising its target price on the healthcare stock to 52 cents from 41 cents previously, which is pegged to 25 times P/E on

SINGAPORE (Sept 18): CIMB Research is upgrading its call on Raffles Medical Group (RMG) to “add” from “reduce” with a lower price target of $1.21 from $1.25 previously on the belief that the stock is looking attractive to gain exposure to the grow

This article appeared in Issue 790 (July 31) of The Edge Singapore

SINGAPORE (July 31): Billionaire former stockbroker Peter Lim is on his way to transforming Rowsley into a healthcare company — by injecting into the public-listed company assets that are already familiar to the market.

SINGAPORE (July 6): Deutsche Bank Wealth Management is retaining its “overweight” stance on emerging market (EM) equities, particularly Asia ex-Japan, as it deems the region’s economic landscape as supportive and its valuations reasonable.

SINGAPORE (June 29): RHB is maintaining its “buy” call on TalkMed Group with a lower target price of 73 cents from $1.03 previously following Wednesday’s news of the eight-month suspension of its CEO, Dr Ang Peng Tiam, starting from July 25.